Get the Stockscreener App
8.40
0.24%
-0.02
After Hours:
8.40
Mbx Biosciences Inc stock is traded at $8.40, with a volume of 140.65K.
It is down -0.24% in the last 24 hours and down -25.13% over the past month.
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$8.42
Open:
$8.42
24h Volume:
140.65K
Relative Volume:
0.48
Market Cap:
$280.71M
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-5.3664
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
-10.54%
1M Performance:
-25.13%
6M Performance:
-60.43%
1Y Performance:
+0.00%
1-Day Range:
$8.30
$8.96
1-Week Range:
$8.30
$9.80
52-Week Range:
$8.30
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
8.40 | 280.71M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences Inc Reports Q4 2024 Net Loss of $15.6 Million, S - GuruFocus.com
MBX Biosciences reports Q4 EPS (47c), consensus (59c) - MSN
MBX Biosciences stock jumps 5% on clinical trial progress - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail™ Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025 - Nasdaq
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide - Yahoo Finance
Rhumbline Advisers Purchases New Stake in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences Announces Additions to Leadership Team - GlobeNewswire
MBX Biosciences strengthens leadership team with new SVPs By Investing.com - Investing.com Canada
MBX Biosciences Announces Additions To Leadership Team -March 05, 2025 at 08:53 am EST - Marketscreener.com
MBX Biosciences strengthens leadership team with new SVPs - Investing.com India
MBX Biosciences, Inc.’s Lock-Up Period Will Expire on March 12th (NYSE:MBX) - Defense World
MBX Biosciences Completes Enrollment In Phase 2 Avail Trial Of Canvuparatide For HP - Nasdaq
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - The Manila Times
MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109 - TipRanks
Can This Overenrolled Clinical Trial Transform Hypoparathyroidism Treatment? - StockTitan
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 47,502 Shares of Stock - MarketBeat
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Purchases 143,170 Shares of Stock - MarketBeat
Major Stakeholders Double Down on MBX Biosciences with Substantial Stock Purchases! - TipRanks
OrbiMed Advisors makes $2 million investment in MBX Biosciences By Investing.com - Investing.com India
Mbx biosciences director Carl Gordon purchases over $2 million in stock - Investing.com
Mbx biosciences director Carl Gordon purchases over $2 million in stock By Investing.com - Investing.com South Africa
MBX Biosciences to Participate in March Investor Conferences - GlobeNewswire
Inside MBX Biosciences' Strategic Move: Key Healthcare Conference Presentations Revealed - StockTitan
BIO CEO 2025: The quest for next-gen obesity meds - BioWorld Online
Reviewing Maravai LifeSciences (NASDAQ:MRVI) and MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences Inc (MBX) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Analytical Overview: MBX Biosciences Inc (MBX)’s Ratios Tell a Financial Story - The Dwinnex
Investing in MBX Biosciences Inc (MBX) Is Getting More Attractive - Knox Daily
Maravai LifeSciences (NASDAQ:MRVI) & MBX Biosciences (NYSE:MBX) Critical Comparison - Armenian Reporter
MBX Biosciences, Inc. (NYSE:MBX) CEO Purchases $534,500.00 in Stock - MarketBeat
The Future of MBX Biosciences Inc: Analyzing MBX - The InvestChronicle
12 Health Care Stocks Moving In Thursday's Pre-Market SessionInvivyd (NASDAQ:IVVD) - Benzinga
MBX Biosciences Director Makes Bold Stock Move - TipRanks
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
MBX Biosciences to Participate in Upcoming February Investor Conferences - The Manila Times
MBX Biosciences CEO to Present at Three Major Healthcare Investor Conferences in February - StockTitan
16,400 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by Barclays PLC - Defense World
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket - Benzinga
Geode Capital Management LLC Invests $579,000 in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Long-acting MBX 2109 may offer more convenient symptom relief - Hypoparathyroidism News
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia - Yahoo Finance
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action - AOL
MBX Biosciences (NYSE:MBX) Shares Gap DownTime to Sell? - MarketBeat
MBX 1416 shows promise in Phase 1 trial for hypoglycemia treatment - Investing.com India
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):